Covered Call ETFs: Smart Income Tool or Overpriced Compromise?
Losing money hurts more than winning feels good, and covered call ETFs are built entirely around that fear. But is the peace of mind they buy worth the price?
Going Back to the Well in a Sector That’s Working
After years of underperformance, biotech is finally catching a nice bid. Here’s my strategy on a name showing promise.
Wendy’s Goes Full Meme: How I’m Riding the Reddit Momentum
This is nothing more than a trading vehicle, but a double stack of Wall Street Bets and 38% short interest makes it appetizing.
Options Trading: Taking a Shot on Celestica After Last Week’s Hit
The stock has come down sharply from the highs and looks poised for a strong bounce.
While Everyone Was Selling, I Initiated a New Position in This Mid-Cap Biotech
I made exactly one trade Friday — and I went to Denmark to do it.
While Everyone’s Swinging for the Fences, I’ll Continue to Hit Singles
Extreme concentration and 100x earnings multiples aren’t my game. This off-the-radar tech trade is.
Down 20%, Activist Involved, Insiders Buying: I’m Going With the Flow
With earnings still growing and Starboard circling, I’m using this strategy around a ‘mundane’ industrial.
Citigroup and I Are Aligned on These 3 Mid-Cap Biopharma Stocks
These names have attractive risk/reward profiles in an overbought market.
A Low-Priced Biotech Is Back in the Bargain Bin – And I’m Adding
This beaten-down small-cap offers rich options premiums, and an attractive setup.
Doug Kass: A Market Bacchanal Rages On, While I Remain Celibate
Despite the market’s amazing advance, there are many justifiable reasons for our doubt and skepticism.